Novo Nordisk Gains as Ozempic Found To Lower Dementia Rates

American depositary receipts (ADRs) of Novo Nordisk (NVO) roseate successful intraday trading Friday aft nan merchandise of an Oxford study that showed nan Danish company’s Ozempic glucosuria supplier was linked to little rates of dementia and a scope of intelligence problems.

The researchers said in The Lancet’s eClinicalMedicine journal that patients had a 48% little consequence of dementia aft a twelvemonth connected Ozempic versus those who had taken an older drug, sitagliptin.

Novo Nordisk Also Seeing Whether Active Ingredient Can Treat Alcoholism

The study is nan latest to show that semaglutide, nan progressive constituent successful some Novo Nordisk’s Ozempic and its obesity medicine Wegovy, tin dainty much than glucosuria aliases weight loss. The patient has been seeking to grow nan uses of its blockbuster treatments, including whether it tin trim intoxicant intake and dainty alcoholic liver disease, Bloomberg noted.

Novo Nordisk ADRs were up 2.6% to $143.39 arsenic of 11 a.m. ET, bringing their year-to-date summation to astir 40%. Shares of Eli Lilly (LLY), which manufactures rival medications Mounjaro and Zepbound, besides person taken disconnected amid soaring income of weight-loss drugs, adding 62% year-to-date.